MedPath

Depth of Anesthesia on Postoperative Delirium and Cognitive After Surgery

Not Applicable
Not yet recruiting
Conditions
Surgery-Complications
Delirium, Postoperative
Anesthesia
Delirium
Cognitive Decline
Cognition Disorder
Interventions
Behavioral: Depth of anesthesia titration using pEEG
Registration Number
NCT06268080
Lead Sponsor
Auckland City Hospital
Brief Summary

The goal of this clinical trial (Balanced-2 study) is to compare light to deep general anesthesia using widely available brain monitors, to see if 'light' anesthesia could reduce rates of delirium, cognitive decline, and disability in older adults undergoing major surgery.

Delirium is the most common serious surgical complication, occurring in an estimated one in four older adults undergoing major surgery. Delirium causes significant distress to patients and family, and is associated with prolonged hospital stay, physical disability, progression to dementia-like illnesses, and discharge to long-term care. Between 10 - 30% of adults aged 70 years and above have surgery every year, and preserving brain health and wellbeing is an important priority during this time.

Older adults (aged ≥65 years, or Indigenous, Pasific patients aged ≥55 years) undergoing major surgery with general anesthesia (excluding heart and brain surgery) and able to provide consent will be able to participate. Participants will be randomized to two groups - a lighter general anesthesia group and a deeper general anesthesia group using processed electroencephalography (a brain monitor that provides information on depth of anesthesia using brain waves). The anesthesiologist will titrate anesthetic drugs according to the brain monitor. Participants will be followed up to determine if they experience delirium after surgery, and longer term impact of delirium such as cognitive and physical decline will also be measured.

If found to be effect, this simple, cheap, and widely available treatment could reduce disability, preserve brain health and wellbeing of many older adults undergoing surgery worldwide, and save millions in healthcare dollars.

Detailed Description

The Balanced-2 study is a randomized clinical trial studying the effects of depth of anesthesia on the incidence of postoperative delirium, and its associated longer-term impact including cognitive, physical decline and mortality. The study follows accumulating evidence that titrating general anesthesia (GA) using processed electroencephalography (pEEG) can reduce the incidence of postoperative delirium, and has the most immediate promise as a preventative strategy.

The evidence to date is limited by 1) significant statistical heterogeneity between studies, 2) poor adherence to the intervention, resulting in poor or no separation between the intervention and standard care groups in some studies, 3) exclusion of high risk patients such as those with cognitive impairment, 4) evidence limited to inhalation anesthetic agents only.

The Balanced-2 study will recruit participants who are at higher risk of postoperative delirium (based on eligibility criteria), undergoing major surgery with total intravenous anesthesia (TIVA), with robust processes to ensure adherence and group separation. Participants will be randomized in a 1:1 ratio using a web-based service in permuted blocks of 8 patients according to region and stratified by surgical urgency and pre-existing neurocognitive disorders, to either light GA or deep GA from 10 mins after induction of anesthesia to emergence. Depth of anesthesia will be titrated using pEEG monitors such as the commonly used Bispectral index (BIS) and Patient State Index (PSI). The procedural anesthesiologist will pre-specify an individual mean arterial pressure (MAP) target before randomisation to avoid confounding. There will be limitations on the use of ketamine, nitrous oxide, clonidine and dexmedetomidine due to interference with pEEG, but all other aspects of care are determined by the procedural anesthesiologist or according to standard institutional protocol.

The sample size was based on calculations using the minimum clinically important effect size, as determined by a Delphi process with 2 stakeholder groups. A statistical analysis plan will be published prior to trial commencement.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
2766
Inclusion Criteria
  • Patients aged ≥ 65 years, and Māori, Pacific or Indigenous participants aged ≥ 55 years who are undergoing major elective or non-elective surgery with expected surgical duration ≥ 2 hours and postoperative hospital stay ≥ 2 nights.
  • Having general anesthesia using total intravenous anesthesia (TIVA) with pEEG monitoring
  • Able to provide informed consent (including patients with mild preoperative neurocognitive disorders)
Exclusion Criteria
  • Intracranial or cardiac surgery
  • Undergoing surgery with 'wake up' test
  • Previous enrollment in Balanced-2 study
  • Terminal illness with expected survival <3 months
  • Emergency surgery within 6 hours of presentation to hospital
  • Cognitive impairment with no capacity to consent or activated enduring power of attorney
  • Clinically impaired and unable to consent due to acute pathology or preoperative delirium

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Light general anesthesiaDepth of anesthesia titration using pEEGBispectral Index (BIS) of 55
Deep general anesthesiaDepth of anesthesia titration using pEEGBispectral Index (BIS) of 40
Primary Outcome Measures
NameTimeMethod
Incidence of postoperative delirium (POD)Administered twice a daily for up to 3 postoperative days or until discharge if discharge occurs before day 3, including weekends. Further once daily testing from days 4 to 7 if screens positive.

Assessed using the Three-minute Diagnostic Interview for the Confusion Assessment Method (3D-CAM) or if patients are in the intensive care unit (ICU), the Confusion Assessment Method for the ICU (CAM-ICU). Delirium testing will occur between 0600 and 1000 and 1800 to 2200 daily including weekends.

Delirium is present if both features (1) altered mental status/fluctuating course and (2) inattention are present, and features (3) altered level of consciousness, OR (4) disorganized thinking are present.

Secondary Outcome Measures
NameTimeMethod
Incidence of severe delirium7 days after surgery

Assessed using Confusion Assessment Method - Severity Short Form (CAM-S)

The CAM-S uses the 4 features of delirium and rates them as absent, mild or marked. Possible scores are o to 7, with higher scores indicating more severe delirium.

Incidence of new mild and major postoperative neurocognitive disordersAssessed at 90 days and 1 year after surgery

Diagnosis of new postoperative neurocognitive disorder requires 1) subjective complaint using standardized questionnaire, 2) objective testing using Mini-Addenbrooke's Cognitive Examination (ACE), and for a diagnosis of major postoperative neurocognitive disorder, 3) evidence of functional decline using Lawton-Brody's instrumental activities of daily living (ADL) scale.

The Mini-ACE questionnaire is scored out of 30, with lower scores indicating more severe cognitive impairment. The Lawton-Brody's instrumental ADL scale is scored out of 8 for women, and 5 for men, with higher scores indicating more independence.

Postoperative cognitive declineAssessed at 90 days and 1 year after surgery

Defined by a 2 or more-point drop in Mini-Addenbrooke's Cognitive Examination scores.

The Mini-ACE questionnaire is scored out of 30, with lower scores indicating more severe cognitive impairment.

Functional declineAssessed at 90 days and 1 year after surgery

As measured by the change in Lawton-Brody's instrumental ADL scores

The Lawton-Brody's instrumental ADL scale is scored out of 8 for women, and 5 for men, with higher scores indicating more independence.

All-cause mortalityAssessed at 1 year after surgery
Duration of delirium7 days after surgery

Duration of delirium for the first 7 days after surgery

Trial Locations

Locations (1)

Auckland City Hospital, Health New Zealand

🇳🇿

Grafton, Auckland, New Zealand

© Copyright 2025. All Rights Reserved by MedPath